other material
confidence high
sentiment positive
materiality 0.70
Citius subsidiary reports Phase 1 data: LYMPHIR + CAR-T shows 86% ORR, 57% CR in high-risk DLBCL
Citius Pharmaceuticals, Inc.
- ORR 86% at 1 month (57% CR, 29% PR) in 14 patients with relapsed/refractory DLBCL.
- One-year PFS 77% (95% CI: 43–92%); one-year OS 84% (95% CI: 49–96%).
- Well-tolerated: no dose-limiting toxicities, no Grade≥3 LYMPHIR-related immune AEs.
- Single LYMPHIR dose depleted circulating Tregs (median reduction 24 Tregs/µL).
- Study conducted at Univ of Minnesota and City of Hope; presented at 2026 Tandem Meetings.